AstraZeneca and BMS Receive Award from Major Medical Association
News May 09, 2013
The ACE Philanthropic Award is presented to an industry partner who is a member of the Corporate AACE Partnership (CAP) and has made a charitable contribution to ACE in support of the betterment of endocrine care and public health.
AstraZeneca and Bristol-Myers Squibb formed the diabetes alliance and entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for Type 2 Diabetes.
“The AstraZeneca/Bristol-Myers Squibb Diabetes Alliance is honored to be recognized with the ACE Philanthropic Award,” said Shoba Ravichandran, M.D., Group Director, AstraZeneca/Bristol–Myers Squibb Diabetes Alliance. “We share the association’s mission of providing high quality care to patients and supporting clinicians, educators and scientists in their work to overcome the burdens of diabetes and other endocrine related diseases.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE